Cerebrospinal fluid (CSF) proteomics plays a crucial role in Alzheimer's Disease (AD) and dementia research by identifying biomarkers that reflect pathological changes in the brain. Researchers analyze CSF to detect specific proteins associated with AD, such as amyloid-beta and tau proteins, which accumulate abnormally in the brains of affected individuals. These biomarkers aid in early diagnosis, tracking disease progression, and evaluating treatment responses.
In recent studies, advancements in proteomic techniques have allowed for more comprehensive profiling of CSF proteins, offering insights into the molecular mechanisms underlying AD and dementia. This approach not only enhances our understanding of disease pathology but also holds promise for developing targeted therapies aimed at modifying disease progression. Thus, CSF proteomics serves as a critical tool in both clinical diagnostics and therapeutic development for AD and related dementias.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Association between APOE allele prevalence and Alzheimer's disease risk in Southwestern Uganda
Frank Balikoowa, African Research Center for Ageing & Dementia, Uganda
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia
Title : Association between depressive symptoms and cognitive impairment severity in a real-world memory clinic cohort
Yun Ju Hsieh, Taipei City Hospital, Taiwan
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China